Get the Stockscreener App
12.28
3.08%
-0.39
Aardvark Therapeutics Inc stock is traded at $12.28, with a volume of 77,056.
It is down -3.08% in the last 24 hours and down -17.25% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$12.67
Open:
$12.49
24h Volume:
77,056
Relative Volume:
0.40
Market Cap:
$267.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.77%
1M Performance:
-17.25%
6M Performance:
+22.31%
1Y Performance:
+0.00%
1-Day Range:
$12.00
$12.66
1-Week Range:
$11.51
$13.58
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
12.28 | 275.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | B. Riley Securities | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-12-25 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Raymond James | Strong Buy |
| Nov-07-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
Aardvark Therapeutics announces leadership appointments - marketscreener.com
Aardvark Therapeutics Launches Dermatology Unit, Names Bryan Jones as Ardia CEO - marketscreener.com
Aardvark Therapeutics, Inc. Announces Appointment of Executive, Effective February 9, 2026 - marketscreener.com
Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline - Nasdaq
Aardvark Therapeutics Appoints Derrick Li as Chief Business Officer; Gives CFO Nelson Sun Additional Role of COO - marketscreener.com
Aardvark Launches Ardia Dermatology Unit, Realigns Leadership - TipRanks
Aardvark Therapeutics Announces Leadership Appointments - Bitget
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer - The Manila Times
Aardvark creates Ardia to develop psoriasis and severe skin treatments - Stock Titan
Aardvark Therapeutics' (AARD) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Aardvark Expands PWS Phase 3 Trial to Younger Children - TipRanks
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility - TradingView
Aardvark Therapeutics Announces FDA Submission and IRB - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Undervalued Obesity Innovator: Justifying a Buy on Aardvark’s Dual Rare-Disease and Mainstream Metabolic Opportunity - TipRanks
HC Wainwright Reiterates "Buy" Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 12% HigherTime to Buy? - MarketBeat
Insider Stock Buying Reaches US$875.0k On Aardvark Therapeutics - 富途牛牛
B.Riley initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Smart Money: Does Aardvark Therapeutics Inc have declining or rising EPSCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
Ten new option listings and two option delistings on January 22nd - TipRanks
Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target - TipRanks
Market Outlook: Can Aardvark Therapeutics Inc expand its profit marginsJuly 2025 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28% - Yahoo Finance
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher – Time to Buy? - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% HigherTime to Buy? - MarketBeat
Treasury Yields: How Aardvark Therapeutics Inc stock compares to growth peersJuly 2025 Summary & Long-Term Capital Growth Ideas - Bộ Nội Vụ
RSI Check: Can Aardvark Therapeutics Inc stock rebound after recent weaknessMarket Activity Summary & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Aardvark Therapeutics updates investor presentation on hunger therapies - TipRanks
Aardvark Therapeutics, Inc Updates Corporate Presentation - TradingView — Track All Markets
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com
What risks investors should watch in Aardvark Therapeutics Inc. stockBull Run & Safe Capital Growth Tips - ulpravda.ru
Can Aardvark Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Comprehensive Market Scan Insights - Улправда
Will Aardvark Therapeutics Inc. stock deliver consistent dividendsPortfolio Return Report & AI Powered Buy/Sell Recommendations - Улправда
Fed Watch: How Aardvark Therapeutics Inc. stock trades during market volatility2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Nasdaq Moves: How Aardvark Therapeutics Inc. stock trades during market volatilityQuarterly Portfolio Summary & Technical Buy Zone Confirmation - Улправда
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):